cyrilzakka/clinical-trials huggingface dataset:
Effect of Exercises on Convergence Insufficiency in Individuals With Temporomandibular Disorders

Temporomandibular Disorder is a disorder that involves the muscles of mastication, the temporomandibular joint (TMJ), and associated structures. Convergence insufficiency (CI) is characterized by the inability of the eyes to perform the eye adduction movement together, to focus on a nearby object. Studies show that there is a relationship between the presence of TMD and its signs and symptoms in patients with convergence insufficiency. Given this, the research question of this clinical trial is whether the effect of oculomotor therapy would be effective in improving the signs and symptoms of Temporomandibular Disorder. The design of this research is a Clinical Trial, Randomized and Blind. It will be divided into two moments: evaluation and intervention. The evaluations will be carried out using the Diagnostic Criteria for Temporomandibular Disorders: Fonseca Anamnestic Index (IAF), Clinical Protocol and Assessment Instruments (DC/TMD), Mandibular function Impairment Questionnaire (MFIQ), Numerical Pain Scale (END), Convergence Test, Meersseman Test and Convergence insufficiency symptom Survey (CISS). Individuals will be randomized into 2 groups: Group A (Treatment for Temporomandibular Disorder) and Group B (Treatment Oculomotor plus Treatment for Temporomandibular Disorder). Both groups will receive physiotherapeutic treatment for 12 weeks. Patients will be reassessed shortly after treatment, 3 and 6 months later. For data analysis, the statistical significance considered will be p\<0.05.


Eligibility Criteria:
Inclusion Criteria:

* Age between 18 and 60 years;
* Presence of pain in the facial region in the last 6 months;
* Presence of pain, at least 3 on the numeric pain scale (END), in the Temporomandibular Joint and/or masticatory muscles and in the last 6 months;
* Diagnosis of myogenic Temporomandibular Disorder, by DC/TMD;
* Moderate and Severe Temporomandibular Disorder carrier, according to Fonseca's Anamnestic Index;
* Presence of Insufficiency of Convergence according to Convergence Test (TC) and by Convergence insufficiency symptom Survey (CISS).

Exclusion Criteria:

* Permanent strabismus;
* History of strabismus surgery;
* History of cervical and/or craniofacial trauma/surgical procedure;
* History of ocular nerve injury;
* Neurological disorders;
* disc disease ;
* Systemic diseases;
* Fibromyalgia diagnosis;
* Previous treatments for TMD carried out in the last 3 months;
* Previous treatments of Convergence Insufficiency with oculomotor therapy (no more than 2 months of treatment in the last year);
* Occlusal treatment in progress;
* Any ocular or systemic medication known to affect accommodation or vergence ;
* Systemic diseases that affect ocular accommodation, vergence , and motility, such as multiple sclerosis, Graves' thyroid disease, myasthenia gravis, diabetes, and Parkinson's disease;
* In continuous use of analgesics, anti-inflammatories, anxiolytics and/or antidepressants;
* Pregnant women.
Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis

We have to be aware of the challenge and concerns brought by 2019-nCoV to our healthcare workers. Front-line healthcare workers can become infected in the management of patients with COVID-19; the high viral load in the atmosphere, and infected medical equipment are sources for the spread of SARS-CoV-2. If prevention and control measures are not in place, these healthcare workers are at great risk of infection and become the inadvertent carriers to patients who are in hospital for other diseases. Nowadays a question that has not yet been clarified by science has been arises: is hydroxychloroquine associated with zinc compared to ivermectin associated with zinc effective as a prophylaxis for asymptomatic professionals involved in the treatment of suspected or confirmed case of COVID-19?

The study is a open-blind, randomised trial that will be conducted in asymptomatic professionals working in areas of high exposure and high risk of transmission of SARS-COV-2.

After obtaining fully informed consent, the investigator will recruit workers in areas of high exposure and high risk of transmission of SARS-COV-2.

Participants will be divided into 2 groups:

* Hydroxychloroquine (HCQ) = 400mg twice on day 1, 400mg/day on day 2, 3, 4, and 5 followed by 400mg once every 05 days, for the next 7 weeks associated with 20 milligrams twice on day of active zinc for 45 consecutive days;
* Ivermectin (IVM) = Dosage guidelines based on participant body weight, once on day for 2 consecutive days, This dose schedule should be repeated every 14 days for 45 days associated with 20 milligrams twice on day of active zinc.

Eligibility Criteria:
Inclusion Criteria:

* Aged 18 - 70 years;
* Professionals working in areas of high exposure and high risk of transmission of SARS-COV-2;
* Understands and agrees to comply with planned study procedures;
* Signed informed consent for participation in the study.

Exclusion Criteria:

* Pregnancy or breastfeeding;
* Major allergy to Hidroxychloroquine, chloroquine or 4-aminoquinolines;
* Serum potassium lower than 3.4 mEq/l;
* Serum magnesium lower than 1.7 mg/dL;
* QTc interval \> 470 ms for man and \> 480 ms for woman;
* Weight \< 40 kg;
Investigating the Effect of Interval Walking and Qigong on People With Knee Osteoarthritis: Pilot Study

Knee osteoarthritis (KOA) causes pain and limited function that leads to a sedentary lifestyle. The sedentary lifestyle increases the risk of cardiovascular diseases. In addition, many subjects with KOA have knee pain and sleep disturbance that limit their function, quality of life and cause body fatigue. Walking exercise can benefit people with KOA. However, continues walking for more than 30 minutes can increase pain that may stop people from participation in walking exercise.

Interval walking may complete the same amount of walking exercise in several separate time periods, without causing extra pain in people with KOA. Mind-body exercise may improve sleep and pain in people with KOA.

This study will help researchers to find out whether the interval walking, or mind-body exercise may help people with KOA to improve their pain, fitness level, sleep quality, exercise participation, fatigue, and quality of life.

By doing this study, researchers hope to learn more about the interval walking or mind-body exercise in people with KOA.


Eligibility Criteria:
Inclusion criteria are the following:

1. 60-79 years of age and diagnosed with KOA by a physician or meet the ACR criteria (95% sensitivity, and 69% specificity) for KOA. The ACR criteria include experiencing almost daily knee pain and having at least 3 of these 6 criteria: (1) Age more than 50 years old, (2) less than 30 minutes of morning stiffness, (3) increased warmth of the knee, (4) crepitus with flexion or extension, (5) joints' bony enlargement , and (6) tenderness of joint line with palpation, or subject must be diagnosed radiologically, with grade II or more according to the Kellgren and Lawrence rating scale.
2. Frequent knee pain or aching on most of the preceding 30 days.
3. An average of mild to moderate pain intensity level (5 to 75 mm on the 100 mm VAS) in the last 7 days
4. Sedentary lifestyle assessed using 2011 Compendium of Physical Activities questionnaire. The subject is considered sedentary if engaging in exercise or physical activity with metabolic equivalents of task (MET) less than 4, not more than two times/week.

Exclusion criteria:

1. Unwilling to attend 3 sessions/week at Kirmayer Fitness Center
2. Having other types of arthritis such as rheumatoid arthritis or gout
3. Neurological disorders
4. CVD including hypertension that prevent them from engaging in walking exercise
5. Currently using beta blocker medication
6. Underwent any lower limb surgery during the past 6 months
7. A history of two or more incidents of fall during the last 6 months
8. Current hip or spine pain that prevents them from engaging in walking exercise.
Outcome of Combined Botulinum Toxin A Injection and Gastric Balloon Implantation in Obesity Treatment

Obesity, which is defined as the accumulation of fat in the body to a degree that impairs health, is defined as a serious public health problem and it is estimated that 13% (approximately 650 million) of the entire world population is obese.

There are different methods in the fight against obesity, one of these methods is bariatric interventions. Although bariatric surgery is the most effective of these procedures, the tendency to endoscopic methods is increasing due to the surgical risk. Gastric balloon is the most common endoscopic method. In addition, gastric botox is among the methods used.

Health consequences of endoscopic interventions have been widely investigating and while gastric balloon recommended as safe and effective method, the situation for gastric botox is controversial.

Although it seems as gastric balloon is an office procedure and safely performed, especially the first week is difficult process for patients. It can also end with abdominal pain, nausea, retching, and eventually a process leading to premature removal of the balloon. In Italian study, Genco et al. reported that out of 2515 patients 11 patients (0.44%) balloon removed due to psychological intolerance. While the reported rate of early gastric balloon removal generally ranges from 0.44% to 16%, De Castro ML. et al. reported the early removal rate as 20%. While the complications related to the gastric balloon are as stated, problems such as nausea, vomiting and cramps after the gastric botox procedure are either not reported or not seen at all.

Therefore, we hypothesize that sequential endoscopic procedures (first botox application followed by gastric balloon placement) will reduce these early complications (abdominal pain, nausea, retching) and early removal of the gastric balloon.

The only study we have reached regarding combined therapy was done in Turkey. Kanlıöz M et al. reported that combining botox and balloon was found to be more effective in losing weight, but it was stated that it had more side effects. In this study, we think that the side effects may already be related to the balloon. As James A et al. stated in their experimental work, the effectiveness of botox is time dependent. It has been stated that the efficacy is optimal after 6 hours in injections to the pyloric region.The fact that the balloon was inserted in the same session, without waiting for enough time after the botox procedure to be effective, may have reduced the possible protective effect of the botox.


Eligibility Criteria:
Inclusion Criteria:

1. patients with body mass index over 30
2. patients who have been on a diet and have done sports at least for 6 month and yet could not lose weight.
3. 18-65 years old patients

Exclusion Criteria:

1. patients diagnosed with peptic ulcer
2. untraceable patients after injection of botulinum toxin A
3. patients with no history of bariatric surgery or interventions
4. patients who do not retrieve balloon after 6 month or require repetitive implantations.
Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease

The goal of this research is to determine if the Tangible Boost system adequately replenishes the Hydra-PEG coating on the surface of a rigid contact lens.

Hydra-PEG is a coating for soft and rigid contact lens, primarily composed of polyethylene glycol-based hydrogel, which is covalently bound to the surface of a contact lens. The Hydra-PEG coating is intended to improve wettability and comfort with contact lenses and is currently FDA approved on a number of contact lenses. For patients with Stevens Johnson Syndrome (SJS) (SS), or Graft versus Host disease (GVHD), diminished efficacy of the Hydra-PEG coating can lead to significant decline in satisfaction with the lenses over time. This is a prospective study to evaluate the efficacy of Tangible Boost, a monthly conditioning solution, to replenish the Hydra-PEG coating on rigid gas permeable contact lenses for patients with SJS, GVHD, and SS. Outcomes from this patient population will be compared to patients with dry eye disease.


Eligibility Criteria:
Inclusion Criteria:

* Written Informed Consent has been obtained prior to any study-related procedures taking place
* Written documentation has been obtained in accordance with the relevant county and local privacy requirements, where applicable
* Male or female
* 18 years of age and older prior to the initial visit
* Is a new or established wearer of PROSE lenses with optimized lens fit prior to enrollment in the study
* Has been diagnosed with Dry Eye Syndrome, SJS, SS, or GVHD
* In the opinion of the investigator, the subject has the ability to follow study instructions
* In the opinion of the investigator, the subject has the ability to complete all study procedures and visits

Exclusion Criteria:

* aphakic (i.e., missing their natural lens inside the eye)
* Is currently participating in any other type of eye-related clinical or research study
* Is pregnant or nursing as reported by the subject
* Has a condition or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound study outcomes, or may significantly interfere with the subject's participation in the study.
* Has a known and self-reported allergy to the following substances: polyethylene glycol, polyvinyl alcohol, triethanolamine, polyquaternium-1, or edetate disodium, which are components of the Tangible Boost and Hydra-PEG systems or care regimen.
* Has had previous ocular surgery within the past 12 weeks
* Adults unable to consent (including adults unable to read and understand English)
* Individuals who are not yet adults (infants, children, teenagers)
* Pregnant women
* Prisoners
* Employees of BostonSight
Effects of Transcutaneous Electrical Phrenic Nerve Stimulation and Transcutaneous Electrical Diaphragmatic Stimulation

Transcutaneous electrical phrenic nerve stimulation (TEPNS) and transcutaneous electrical diaphragm stimulation (TEDS) are modalities that use surface electrodes placed on the patients' skin to generate action potentials and contractions of the muscle fibers of the diaphragm. The primary objective will be to evaluate the efficacy of TEPNS and TEDS in healthy adult individuals. Secondary objectives will be to assess the feasibility, safety, and level of discomfort reported by the individual resulting from the application of TEPNS and TEDS.

This crossover trial, single-blind, bicentric study will be conducted at two hospitals. Adult volunteers aged 18 to 60 years, healthy, with a body mass index between 18.5 and 24.9 kg/m2, without a history of previous respiratory diseases, and without contraindications to undergo evaluation or application of the proposed electrical stimulation modalities will be included. Participants' diaphragm muscle will be assessed using ultrasound for variables such as thickness, thickness fraction, and diaphragm mobility. Patients will be randomized using opaque envelope draw prior to evaluation into two distinct experimental moments: 1) "TEPNS" moment - application of the TEPNS protocol; or 2) "TEDS" moment - application of the TEDS protocol. Additionally, data regarding the feasibility and safety of the application of electrical stimulation modalities will be collected.

Eligibility Criteria:
Inclusion Criteria:

* Age between 18 and 60 years;
* Normal pulmonary function test, without alterations, assessed through spirometry;
* Body Mass Index (BMI) between 18.5 and 24.9 kg/m2.

Exclusion Criteria:

* Smokers or former smokers;
* Individuals with previously known cardiopulmonary diseases (restrictive lung diseases, chronic obstructive pulmonary disease - COPD, asthma, cystic fibrosis, among other pathologies);
* Presence of implanted electrical devices (pacemaker, implantable cardioverter-defibrillator, among others);
* Individuals who have contraindications to undergo evaluation and/or application of transcutaneous electrical stimulation of the diaphragm muscle, such as: altered sensitivity, wounds at the site of application, deformities, among other conditions.
Effect of Umbilical Cord Milking Versus Clamping in Preterms on Cerebral Oxygenation and Ductus Arteriosus Closure

All patients will be subjected to the following:

1-Umbilical cord milking or delayed cord clamping according to the ranamization table 2 serial measurement of cerebral tissue oxygenation 3- serial echocardiography for ductus arteriosus (DA)functional closure

* Study Population: neonates born and admitted to Ain shams university neonatal intensive care units (NICUs).

  * Inclusion criteria:

    o Preterm infants with gestational age (GA) of 28 - 34 weeks born and admitted to Ain shams university NICUs.
  * Exclusion criteria:

    * Late preterm with gestational age 34-37 weeks.
    * Term infants with gestational age \> 37 weeks.
    * NIRS data that was not obtained within 1st hour after birth.
    * Congenital heart disease (other than DA or small atrial septal defects/patent foramen oval/ventriculi septal defects).
    * Hypoxic-ischemic insult.
    * Major congenital deformations. #All participants will be subjected to the following:
* Infants will be considered to be randomized at the time of enrolment for:

  o Delayed cord clamping (DCC) and Umbilical cord milking (UCM)
* Near-infrared spectroscopy (NIRS):

  * In the delivery room: after the intervention (UCM or DCC) the regional cerebral tissue oxygenation (rScO2 ) and cerebral fractional tissue oxygen extraction (c FTOE) will be collected for 10 minutes within 1st hour after birth.
  * In the neonatal intensive care unit: NIRS data will be collected for 2 hours at 12,24 hours, and 48 hours after birth.
* Echocardiography:

will be performed at 6, 12, 18, 24, and 48 hours of life by using an ultrasound Doppler machine Mindary.M9. assessment of DA functioning closure by measuring duct diameter and direction of blood flow through it.

Eligibility Criteria:
Inclusion Criteria:

* Preterm infants with gestational age (GA) of 28 - 34 weeks born and admitted to Ain shams university NICUs.

Exclusion Criteria:

* Late preterm with gestational age 35-37 weeks.

  * Term infants with gestational age \> 37weeks.
  * NIRS data that not obtained within 1sthour after birth.
  * Congenital heart disease (other than PDA or small atrial septal defects/patent foramen oval/muscularventriculoseptal defects).
  * Hypoxic-ischemic insult.
  * Major congenital deformations.
Efficacy of Continuous Skin to Skin Care (Technique Kangaroo: TK) After Birth for Low Birth Weight (LBW) Infants and Their Mothers in Developing Countries

The purpose of this study is to examine the efficacy of Technique Kangourou (TK) between low birth weight (LBW) infants and their mothers started as soon as possible within 24 hours after birth in developing country.

For the purpose of this study, TK is defined as skin-to-skin direct and continuous (24 hours) contact between LBW infants and their mothers or any other people who substitute mothers.


Eligibility Criteria:
Inclusion Criteria:

* Birth weight (BW) \< 2500g
* Delivery at maternity of CHUM (Birth \< 24 hours)
* Without serious congenital malformation
* Sat O2 \>=95％, HR \> 100 / min, RR \< 60 / min, Capillary refilling time \< 3 sec
* The mother and the family are motivated to practice TK.
* The mother and the family available to practise TK should be healthy.

Exclusion Criteria:

* Apnea of prematurity \>20 sec
* With intravenous infusion
The Change of Clinical Features and Surgical Outcomes in Patients With Pressure Injury During the COVID-19 Pandemic: A Retrospective Study

The COVID-19 pandemic has considerably and negatively affected numerous lives and economies worldwide; specifically, it has led to delays in seeking medical treatment among many people \[1-3\]. Delaying or avoiding seeking medical advice can result in worsened symptoms, delayed evaluation, and treatment complications \[4-7\]. Moreover, the pandemic has significantly impacted health-care systems, leading to numerous issues including shortages of medical staff, beds, equipment, medicines, and isolation facilities. The concern of cross-contamination-where COVID-19 may spread within wards unknowingly-has also increased the emotional burden among health-care workers \[8-10\].

Pressure injury (PI) is a common health issue particularly among older people who have physical limitations or are bedridden. PI management often requires a long-term individualized plan. Failure to implement this strategy may influence the quality of life and may cause wound-related psychosocial issues (e.g., low self-esteem), increase health-care expenditures, and shorten survival among the patients \[11\]. Moreover, long-term PIs are prone to infection and bleeding, which may lead to sepsis or anemia \[12-14\].

The current study explored whether COVID-19 pandemic-related changes affected the characteristics and treatment outcomes of patients with PIs.


Eligibility Criteria:
Inclusion Criteria:

* all patients who received debridement or flap-reconstruction surgery for Pressure injury at Wan Fang Hospital from January 2016 to December 2021.

Exclusion Criteria:

* Patients who underwent debridement or flap-reconstruction surgery across the pre-COVID and COVID periods were excluded from the study.
Residual Platelet Activity Despite Aspirin Utilization in Coronary Heart Disease

The purpose of this study is to compare the response to aspirin in the acute phase with the late phase of an acute coronary syndrome.

The purpose of this study is to compare, in the same population, the response to aspirin in the initial phase (first 48 hours) with the late phase (after 3 months of discharge)of a non ST elevation acute coronary syndrome (angina or acute myocardial infarction).

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years
* Confirmed diagnosis of acute coronary syndrome without ST segment elevation, in the first 48 hours after the onset of the clinical symptoms
* Regular use of aspirin for at least seven days.

Exclusion Criteria:

* Previous use, in the last 7 days, of another antiplatelet agent than aspirin
* Use of antivitamin K in the last 3 weeks
* Hemoglobin \< 10g/dL and / or hematocrit \< 30% or \> 50%, platelets count \< 100.000/mm3 or \> 500.000/mm3, creatinine clearance \< 30 mL / minute
* Killip class III or IV
* Need for vasopressor or inotropic parenteral medication at inclusion in the study
* Percutaneous coronary intervention within 30 days or CABG in the last 90 days prior to study entry
* Current malignancy
* Hematologic diseases
* Refusal to sign the inform consent form
* Unable to attend the second visit (follow-up) for any reason except for death